RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $34 from $30 and keeps an Outperform rating on the shares after its Q1 results. On ele’, RBC thinks the result is a win for Viridian’s subQ program as a 35%-39% delta beat its expectations of 20%-30%, and demonstrated ele’ could perform on par with IV Tepezza and Veli’ in chronic TED, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics: REVEAL-2 Success and Strong Cash Runway Support Buy Rating, $32 Price Target Unchanged
- Analyst Reiterates Buy as Strong Phase III REVEAL-2 Data Boost Elegrobart’s Regulatory and Commercial Outlook
- Viridian Reports Positive Phase 3 Results in Thyroid Eye Disease
- Viridian announces REVEAL-2 phase 3 study met primary endpoint
- Viridian Therapeutics reports Q1 EPS (90c), consensus ($1.09)